EPREX 2000 # Price

Overview

Welcome to Dwaey, specifically on EPREX 2000 # Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Erythropoietin (human recombinant).
EPREX 2000 # is available in the market in concentration 2000 IU/Syringe and in the form of Injection/Solution for.

JANSSEN-CILAG AG is the producer of EPREX 2000 # and it is imported from SWITZERLAND, The most popular alternatives of EPREX 2000 # are listed downward .

Mode Of Action

Erythropoietin regulates erythropoiesis by stimulating the differentiation and proliferation of erythroid precursors, stimulating the release of reticulocytes into the circulation, and synthesis of cellular haemoglobin. Recombinant human erythropoietin is available as epoetin alfa and epoetin beta which are used in the management of anaemias associated with CRF, cancer chemotherapy and anti-AIDS drug zidovudine.

Indication

• Anemia associated with Chronic Renal Failure
• including patients on dialysis (ESRD) and patients not on dialysis
• Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy
• Anemic patients (hemoglobin > 10 to < 13 g/dL) scheduled to undergo elective
• noncardiac
• nonvascular surgery to reduce the need for allogeneic blood transfusions
• Anemia related to therapy with zidovudine in HIV-infected patients.

Precaution

Erythropoietin should be used with caution in those patients with controlled hypertension, ischaemic vascular disease, history of seizures, or suspected allergy to the product. Iron evaluation: Prior to and during Epoetin therapy, the patient's iron stores, including transferrin saturation and serum ferritin, should be evaluated. Transferrin saturation should be at least 20%, and ferritin should be at least 100 ng/mL. Virtually all patients will require supplemental iron to increase or maintain transferrin saturation to levels that will adequately support erythropoiesis. Lactation: Unknown whether drug is excreted in breast milk; use with caution; avoid administering multidose vials

Side Effects

• >10% Pyrexia (10-42%)
• Nausea (11-35%)
• Hypertension (14-27%)
• Cough (4-26%)
• Vomiting (12-28%)
• Pruritus (12-21%)
• Rash (2-19%)
• Headache (5-18%)
• Arthralgias (10-16%) 1-10% Arthralgia (10%)
• Myalgia (10%)
• Stomatitis (10%)
• Diarrhea (9%)
• Dizziness (9%)
• Edema (9%)
• Fatigue (9%)
• Weight decrease (9%)
• Medical device malfunction (artificial kidney clotting during dialysis) (8%)
• Vascular occlusion (vascular access thrombosis) (8%)
• Vomiting (8%)
• Asthenia (7%)
• Chest pain (7%)
• Injection-site irritation (7%)
• Muscle spasm (7%)
• Upper respiratory tract infection (URTI) (7%)
• Urticaria (3%)
• Seizures (2.5%)
• Pulmonary embolism (1%)
• Respiratory tract congestion (1%) Potentially Fatal: Hypertensive crisis with encephalopathy-like symptoms e.g. headache
• confusion
• generalised seizures. Thrombosis.

Contra indication

Uncontrolled hypertension, hypersensitivity to mammalian cell products and human albumin.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks